Astrocyte Pharmaceuticals
Astrocyte Pharmaceuticals is dedicated to developing innovative neuroprotection therapies for brain injuries and neurodegenerative disorders such as stroke, TBI, concussion, and Alzheimer's disease. The company focuses on proving the neuroprotective benefits of astrocyte activation and advancing breakthrough therapeutic agents. It collaborates with academic institutions and has received multiple NIH and DOD grants to support its research and development efforts.
Industries
Nr. of Employees
small (1-50)
Astrocyte Pharmaceuticals
Cambridge, Massachusetts, United States, North America
Patents
Compounds and methods for treating neurological and cardiovascular conditions
US-12390483-B2
View DetailsCompounds and methods for treating neurological and cardiovascular conditions
US-12239654-B2
View DetailsCompounds and methods for treating neurological and cardiovascular conditions
US-11484545-B2
View DetailsCompounds and methods for treating neurological and cardiovascular conditions
US-10953031-B2
View Details
Compounds and methods for treating neurological and cardiovascular conditions
US-12390483-B2
View DetailsCompounds and methods for treating neurological and cardiovascular conditions
US-12239654-B2
View DetailsCompounds and methods for treating neurological and cardiovascular conditions
US-11484545-B2
View DetailsCompounds and methods for treating neurological and cardiovascular conditions
US-10953031-B2
View DetailsProducts
Lead clinical candidate — adenosine A3 receptor agonist small molecule
A development candidate small molecule that activates astrocyte‑mediated neuroprotective mechanisms (adenosine A3 receptor agonist class) intended for acute administration in stroke, TBI, concussion, and investigation in neurodegenerative disease models; supported by translational efficacy in multiple species and advanced toward IND and early clinical studies.
AST-004
An investigational treatment in clinical development for concussion and traumatic brain injury designed to enhance astrocyte function and increase energy metabolism to protect the brain.
AST-008
A proprietary drug candidate in preclinical development targeted toward pain and migraine indications.
Lead clinical candidate — adenosine A3 receptor agonist small molecule
A development candidate small molecule that activates astrocyte‑mediated neuroprotective mechanisms (adenosine A3 receptor agonist class) intended for acute administration in stroke, TBI, concussion, and investigation in neurodegenerative disease models; supported by translational efficacy in multiple species and advanced toward IND and early clinical studies.
AST-004
An investigational treatment in clinical development for concussion and traumatic brain injury designed to enhance astrocyte function and increase energy metabolism to protect the brain.
AST-008
A proprietary drug candidate in preclinical development targeted toward pain and migraine indications.
Services
Design and conduct of efficacy studies including repetitive TBI mouse models, rodent stroke models, and NHP transient middle cerebral artery occlusion models in partnership with CROs.
Execution and coordination of GLP toxicology, safety pharmacology, and drug metabolism studies required for regulatory submissions.
Operational leadership for clinical trial design, CRO management, data management, and execution of early‑phase human studies in CNS and acute injury indications.
Development and optimization of clinical formulations, including oral formulations, to support regulatory filings and clinical study needs.
Management of exclusive licensing agreements for university‑derived intellectual property and coordination of sponsored research collaborations.
Design and conduct of efficacy studies including repetitive TBI mouse models, rodent stroke models, and NHP transient middle cerebral artery occlusion models in partnership with CROs.
Execution and coordination of GLP toxicology, safety pharmacology, and drug metabolism studies required for regulatory submissions.
Operational leadership for clinical trial design, CRO management, data management, and execution of early‑phase human studies in CNS and acute injury indications.
Development and optimization of clinical formulations, including oral formulations, to support regulatory filings and clinical study needs.
Management of exclusive licensing agreements for university‑derived intellectual property and coordination of sponsored research collaborations.
Expertise Areas
- Neuroprotection drug discovery
- Preclinical translational studies (rodent and non‑human primate)
- PK/PD and drug metabolism (DMPK) studies
- IND‑enabling toxicology and safety pharmacology
Key Technologies
- Small‑molecule therapeutics
- Adenosine A3 receptor agonists
- Astrocyte‑targeted therapeutic approaches
- Rodent and non‑human primate stroke/TBI models
News & Updates
September 8, 2024
March 12, 2024
September 8, 2024
March 12, 2024